source
- Merck and Moderna present Phase 3 cancer vaccine data at ESMO26 amid Treasury proposal on China investmentEndpoints Weekly reporter Nicole DeFeudis writes from Madrid during the ESMO26 meeting. The most anticipated presentation was a Phase 3 study of a cancer vaccine jointly developed by Merck and Mod…
- AstraZeneca says phase 3 ADC shows strong overall survival despite missing progression-free survival endpointAstraZeneca executives emphasized that the detailed data from their phase 3 study of the next‑generation antibody‑drug conjugate are robust enough to be presented to regulators, even though the tri…